Otsuka Pharmaceutical Development &… — Receipts Report
Foreign owner disclosed
Lobbying client · LD-2 disclosures
Otsuka Pharmaceutical Development & Commercialization, Inc.
Maryland
28 filings from 2 registrants · 2015–2020 · latest filed Jan 20, 2021
Reported on its behalf
$2.4M
every LD-2 on file
Its own filed spend
$990K
lobbying for itself
Fees to outside firms
$1.4M
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: otsuka-pharmaceutical-development-commercialization-inc.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
GOV
1 filing
$190K on those filings
Medicare/Medicaid
MMM
1 filing
$60K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
114th Congress
Innovation Act
9 filingsthrough 2016
S. 1893114th CongressMental Health Awareness and Improvement Act of 20159 filingsthrough 2016
H.R. 1945115th CongressWildlife and Hunting Heritage Conservation Council Advisory Committee Act8 filingsthrough 2018
H.R. 2690115th CongressAgricultural Worker Program Act of 20178 filingsthrough 2018
H.R. 6115th CongressSUPPORT for Patients and Communities Act8 filingsthrough 2018
H.R. 9115th CongressReserved for the Speaker.8 filingsthrough 2018
S. 1893115th CongressSystemic Risk Designation Improvement Act of 20178 filingsthrough 2018
S. 481115th CongressThompson Divide Withdrawal and Protection Act of 20178 filingsthrough 2018
H.R. 6114th Congress21st Century Cures Act8 filingsthrough 2016
H.R. 2690114th CongressIncluding Families in Mental Health Recovery Act of 20157 filingsthrough 2016
H.R. 1945114th CongressTargeted Use of Sanctions for Killing Elephants and Rhinoceros Act of 20156 filingsthrough 2016
S. 1945114th CongressMental Health Reform Act of 20153 filingsthrough 2015
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Molly RyanOtsuka Pharmaceutical Development & Commercialization, Inc.7 filingsthrough 2015
Louis AgnelloAkin Gump Strauss Hauer & FeldCovered position: Snr Cnsl, Joint Econ Committee, Mar 17-Nov 17; Leg cnsl, Sen Heinrich, Apr 14-Mar 17; Leg Asst, Rep Doris Matsui, Dec 11-Apr 14; Leg Asst, Senate Judiciary Committee, May 09-Aug 09; Research Analyst, Senate Small Business Committee, Jun 07-Aug 085 filingsthrough 2019
John BardiOtsuka Pharmaceutical Development & Commercialization, Inc.3 filingsthrough 2015
Richard ThompsonOtsuka Pharmaceutical Development & Commercialization, Inc.2 filingsthrough 2015
John JonasOtsuka Pharmaceutical Development & Commercialization, Inc.2 filingsthrough 2015
Heide BajnrauhOtsuka Pharmaceutical Development & Commercialization, Inc.2 filingsthrough 2015
Karen ThielOtsuka Pharmaceutical Development & Commercialization, Inc.2 filingsthrough 2015
Eli TomarOtsuka Pharmaceutical Development & Commercialization, Inc.2 filingsthrough 2015
Todd TutenOtsuka Pharmaceutical Development & Commercialization, Inc.2 filingsthrough 2015
Covered positions · 3 of 15 lobbyists named on these filings disclosed a prior government post. The text is reproduced exactly as filed.
